| Biomarker ID | 676 |
| PMID | 21705286 |
| Year | 2011 |
| Biomarker | Alkaline Phosphate |
| Biomarker Basis | Expression Based |
| Biomolecule | Others |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 4.33 (95% CI: 1.53–12.21) |
| Effect on Pathways | Pathways Include:- Folate biosynthesis, Bone mineralization regulation, Endochondral ossification, BDNF signaling pathway, FSH regulation of apoptosis |
| Experiment | Progression to Hormone-sensitive Prostate Cancer after ADT |
| Type of Biomarker | Potential Predictive |
| Cohort | 33 patients in the study were chosen such that they all had metastatic disease, 16 had Hormone Sensitive prostate cancer and 17 had Castration Resistant Prostate Cancer. All Patients underwent Androgen Deprivation Therapy |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.006 |
| Method Used | Cellsearch CTC Assay |
| Clinical | No |
| Remarks | Significant only in Univariate Analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ALPL |